Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine

作者：Muscatello Maria Rosaria A^*; Bruno Antonio; De Fazio Pasquale; Segura Garcia Cristina; Pandolfo Gianluca; Zoccali Rocco

来源：Expert Opinion on Pharmacotherapy, 2014, 15(16): 2329-2345.

DOI：10.1517/14656566.2014.956082

• add-on
• clozapine augmentation
• refractory
• treatment-resistant schizophrenia

Introduction: Although clozapine (CLZ) is considered the best evidence-based therapeutic option for treatment of resistant schizophrenia patients, a significant proportion of CLZ-treated patients show a partial or inadequate response to treatment, leading to increased healthcare cost and poor quality of life for affected individuals. %26lt;br%26gt;Areas covered: This paper comprises a review of main research in CLZ augmentation strategies for treatment-refractory schizophrenia, with a focus on research conducted between 1990 and 2014. Databases that were searched include: PubMed, CINAHL, EMBASE PsychINFO, AgeLine and Cochrane Database of Systematic Reviews. Primary search terms were %26apos;clozapine augmentation%26apos;, %26apos;clozapine and add-on%26apos; and %26apos;treatment-resistant schizophrenia%26apos;, with cross reference to specific agents covered in this article. We reviewed the available evidence on CLZ augmentation with antipsychotics, antidepressants, mood stabilizers and other agents. %26lt;br%26gt;Expert opinion: Many drugs have been evaluated as CLZ add-on therapies without demonstrating convincing efficacy in treating refractory schizophrenia symptoms. More research is needed to better define outcomes in schizophrenia, the topic of treatment-resistance and more well-designed trials are required to establish true efficacy and safety of CLZ augmentation strategies.

• 出版日期2014-11